Kenneth Sooi

Supplementary Figure S3 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

Depth of response of EBV DNA (BamHI-W) on FTD/TPI.

Data from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

Abstract Purpose: Therapeutic options beyond platinum, gemcitabine, and immunotherapy in recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) remain limited. Median overall survival (OS) for R/M disease is 20 months. This study evaluated the efficacy and safety of trifluridine/tipiracil (FTD/TPI) in platinum-resistant R/M NPC. Patients …

Supplementary Figure S1 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

Progression free survival of patients on FTD/TPI. Median progression free survival was 6.5 months (95% CI 3.12–9.88).

Supplementary Figure S2 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

Overall survival of patients on FTD/TPI. Median overall survival was 13.1 months (95% CI 6.83–19.38).

Supplementary Figure S4 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

Log2 fold change in plasma thymidylate synthase (TYMS) expression from baseline to pre–cycle 2 following TAS-102, demonstrating upregulation of TYMS following exposure to FTD/TPI.

Supplementary Table S3 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

Treatment exposure and compliance table. Patients received a median of 3 cycles of treatment (range, 1–12), with 17 patients (49%) completing ≥4 cycles. 31 patients (89%) achieving a relative dose intensity (RDI) ≥75%.

Supplementary Table S2 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

Relationship between neutropenia and clinical response on FTD/TPI Fisher’s exact p < 0.001.

Supplementary Table S1 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

S1A: Treatment responses were observed irrespective of prior immune checkpoint inhibitor exposure, with no significant difference in response distribution between the two groups (p = 0.293). S1B:DCR at 12 weeks were observed irrespective of prior immune checkpoint inhibitor exposure, with no significant …

Supplementary Table S4 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

Representativeness of Study Participants.

Supplementary Methods S1 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

Eligibility Criteria.

An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib

Kenneth Sooi, Pongwut Danchaivijitr, C.K. Wong, V. D. Tu et autres

BACKGROUND: Afatinib is an approved first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. At the standard 40 mg dose, 28%-53% of patients in randomized trials required dose reductions due to adverse events (AEs), predominantly cutaneous and gastrointestinal. This …

sg, th, my, vn (code pays fourni par la source)

A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Jia Li Low, Wan Qin Chong, Edwin Pun Hui, Tuan Zea Tan et autres

PURPOSE: Therapeutic options beyond platinum, gemcitabine, and immunotherapy in recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) remain limited. Median overall survival (OS) for R/M disease is 20 months. This study evaluated the efficacy and safety of trifluridine/tipiracil (FTD/TPI) in platinum-resistant R/M NPC. PATIENTS AND …

sg, cn, hk (code pays fourni par la source)